Cerity Partners LLC Purchases 30,801 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Cerity Partners LLC increased its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 200.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,181 shares of the company’s stock after purchasing an additional 30,801 shares during the quarter. Cerity Partners LLC’s holdings in Sana Biotechnology were worth $78,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Bank of New York Mellon Corp raised its stake in Sana Biotechnology by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company’s stock worth $578,000 after acquiring an additional 7,230 shares in the last quarter. Clarius Group LLC raised its position in Sana Biotechnology by 88.9% in the 1st quarter. Clarius Group LLC now owns 212,500 shares of the company’s stock valued at $357,000 after buying an additional 100,000 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in Sana Biotechnology in the 1st quarter worth about $51,000. Pallas Capital Advisors LLC purchased a new stake in Sana Biotechnology in the 1st quarter worth about $29,000. Finally, Rhumbline Advisers increased its holdings in Sana Biotechnology by 5.4% in the 1st quarter. Rhumbline Advisers now owns 182,134 shares of the company’s stock worth $306,000 after acquiring an additional 9,359 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Morgan Stanley initiated coverage on Sana Biotechnology in a research report on Thursday, July 3rd. They set an “overweight” rating and a $12.00 price target for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price target on shares of Sana Biotechnology in a research note on Tuesday, June 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Sana Biotechnology in a research note on Thursday, April 24th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $9.17.

Sana Biotechnology Stock Down 8.8%

NASDAQ:SANA opened at $4.45 on Wednesday. The stock’s fifty day moving average is $3.20 and its two-hundred day moving average is $2.66. Sana Biotechnology, Inc. has a 52 week low of $1.26 and a 52 week high of $7.30. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of -5.06 and a beta of 1.86.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. On average, sell-side analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.